v3.26.1
Note 15 - Segment Information (Tables)
12 Months Ended
Dec. 31, 2025
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
   

Year ended

 
    December 31,  
   

2025

   

2024

 

Revenue

  $ (28 )   $  

Less:

               

Employee expense (not including stock-based compensation)

    5,823       6,212  

Development and clinical trial expense

    3,227       3,385  

Other general and administrative expense(a)

    3,666       4,376  

Other segment loss (income), net(b)

    1,675       (969 )

Discontinued operations

    (73 )      

Segment and consolidated net loss

  $ (14,290 )   $ (13,004 )